The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.

摘要: With a global incidence of 1.8 million cases, colorectal cancer represents one the most common cancers worldwide. Despite impressive improvements in treatment efficacy through cytotoxic and biological agents, cancer-related death burden metastatic (mCRC) is still high. mCRC not genetically homogenous disease various mutations influence development. Up to 12% patients harbor signal transduction molecule BRAF, prominent being BRAFV600E. In mCRC, BRAFV600E mutation well-known negative prognostic factor, associated with dismal prognosis. The currently approved treatments for BRAF-mutated are little impact, there no option superior others. However, gradual molecular understanding over last decades extracellular signal-regulated kinase/mitogen-activated protein kinase pathway, resulted development new therapeutic strategies targeting involved molecules. Recently published ongoing studies administering combination different inhibitors (e.g., MEK, EGFR) showed promising results represent standard care. this review, we present, both, clinical aspects patients, provide an update on current future approaches that might direct therapy era.